Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Advanced Biomed Inc. (ADVB)

Advanced Biomed completes $1.08 million Acellent deal, names Xiaomin Chen CEO in AI pivot

Mixed Impact 4 of 5 leadership Written later

Advanced Biomed completed its acquisition of 100% of Acellent Technologies (Hong Kong) Co. Limited on April 30, 2026, paying with 270,000 newly issued common shares valued at $4.00 each, or $1,080,000 in estimated consideration. The company also said it is pivoting from life sciences to artificial intelligence development, replacing CEO and Chairman Yi Lu with Xiaomin Chen, the seller of the acquired company, effective April 28, 2026.

Key points

  • Acquisition of Acellent Technologies (Hong Kong) completed April 30, 2026, for 270,000 shares valued at $4.00 per share, about $1,080,000 in estimated consideration
  • Yi Lu separated as CEO, director and Chairman under a mutual agreement; he will receive 39,999 shares as severance
  • Xiaomin Chen appointed CEO, director and Chairman effective April 28, 2026, and will receive $12,000 per month under his employment agreement

The filing

CompanyAdvanced Biomed Inc. (ADVB)
Form8-K, current report
Filed with the SECMay 1, 2026, 5:15 PM ET
Accession number0001213900-26-051028

Items reported: 2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.